What blood tests are used to monitor Colorectal Cancer

Blood Tests for Colorectal Cancer Monitoring

Blood tests play an important role in monitoring colorectal cancer patients during and after treatment. Here's what you should know about the main tests used:

CEA (Carcinoembryonic Antigen)

What it is: CEA is a protein that can be elevated in colorectal cancer patients. It's the primary blood marker used for monitoring.

When it's used:

• According to NCCN Guidelines for Colon Cancer, CEA testing is recommended every 3-6 months for the first 2 years after surgery, then every 6 months for a total of 5 years of surveillance
• CEA is only checked if you're a potential candidate for further intervention (meaning if recurrence is found, you might be able to have additional treatment)

Important context: CEA levels can be elevated in other conditions too (smoking, benign diseases), so it's not specific to cancer. Your doctor interprets it alongside imaging and other clinical findings.

---

Complete Blood Count (CBC)

What it measures: Red blood cells, white blood cells, and platelets

Why it matters for colorectal cancer:

• Monitors for anemia (low red blood cells), which can develop during chemotherapy
• Tracks white blood cells to assess immune function and tolerance to treatment
• Checks platelets, which help with blood clotting

---

Chemistry Panel (Metabolic Panel)

What it includes: Tests for kidney function, liver function, electrolytes, and glucose

Why it's important:

• Colorectal cancer can spread to the liver, so liver function tests help detect this
• Chemotherapy drugs can affect kidney and liver function
• Helps ensure your body is tolerating treatment

---

Emerging Blood Tests: Circulating Tumor DNA (ctDNA)

What it is: ctDNA are fragments of cancer DNA that circulate in the bloodstream. This is an emerging technology that's being studied for colorectal cancer monitoring.

Current status according to NCCN Guidelines:

• ctDNA shows promise as a prognostic marker (helps predict risk of recurrence)
• However, ctDNA is NOT currently recommended for routine surveillance outside of clinical trials
• The guidelines note there is "insufficient evidence to recommend routine use of ctDNA assays"
• De-escalation of treatment based on ctDNA results is NOT recommended at this time

Why the caution? While ctDNA can detect molecular recurrence (cancer DNA in blood before symptoms appear), doctors need to know that early detection will actually help you—meaning there needs to be effective treatment available if recurrence is found.

---

Typical Monitoring Schedule

Based on NCCN Colon Cancer Guidelines, here's what surveillance typically looks like:

For Stage II & III disease:

• History and physical exam: every 3-6 months for 2 years, then every 6 months for 5 years total
• CEA blood test: every 3-6 months for 2 years, then every 6 months for 5 years total
• CT imaging: every 6-12 months for 5 years
• Colonoscopy: at 1 year after surgery (with specific follow-up intervals based on findings)

For Stage IV disease:

• More frequent monitoring with CEA and imaging every 3-6 months for the first 2 years

---

Questions to Ask Your Oncologist

1. Which blood tests will be part of MY monitoring plan? (Schedules vary based on stage and individual factors)
2. What CEA level is considered "normal" for me? (Baseline matters—some people have naturally higher levels)
3. If my CEA rises, what happens next? (Does it trigger imaging? Further testing?)
4. Are there any clinical trials involving ctDNA testing I should know about?
5. How often will I have blood work drawn, and when will I get results?

---

Key Takeaway

CEA remains the standard blood marker for colorectal cancer surveillance, combined with imaging and physical exams. While newer tests like ctDNA show exciting potential, they're not yet standard practice outside research settings. Your oncologist will determine the best monitoring schedule for YOUR specific situation based on your cancer stage, treatment received, and individual risk factors.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Sources:

• NCCN Guidelines for Colon Cancer (Version 5.2025) – Surveillance recommendations for stages I-IV
• NCCN Guidelines for Colon Cancer – Principles of Pathologic and Molecular Review regarding ctDNA and emerging biomarkers